Pharmacologic treatment of sex offenders with paraphilic disorder

Current Psychiatry Reports

Volumn 15, Issue 5, 2013, Pages

  Garcia, Frederico Duarte ^a,b   Delavenne, Heloise Garcia ^a   Assumpção, Alessandra De Fátima Almeida ^a   Thibaut, Florence ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITÉ DE ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Androgen Deprivation Therapy; CPA; Cyproterone Acetate; GnRHa; Gonadotropin Releasing Hormone Analog; Goserelin; Leuprorelin; Medroxyprogesterone Acetate; MPA; Paraphilia; Pedophilia; Pharmacologic Treatment; Psychiatry; Selective Serotonin Reuptake Inhibitor; Sex Offender; Sexual Disorders; SSRI; Steroidal Antiandrogen Treatments; Triptorelin

Indexed keywords

ANDROSTANOLONE; CYPROTERONE ACETATE; FLUOXETINE; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; SERTRALINE; TESTOSTERONE; TRIPTORELIN;

ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; MEDICAL ETHICS; PARAPHILIC DISORDER; PSYCHOTHERAPY; RECEPTOR SENSITIVITY; RECIDIVISM; RISK ASSESSMENT; SEXUAL CRIME; TREATMENT DURATION;

EID: 84875831286     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0356-5     Document Type: Article

References (50)

1. Post L, Mezey N, Maxwell N, Wilbert W. The rape tax: tangible and intangible costs of sexual violence. J Interpers Violence. 2002;17(7):773-82. (Pubitemid 36678232)
2. Birger M, Bergman-Levy T, Asman O. Treatment of sex offenders in Israeli prison settings. J Am Acad Psychiatry Law. 2011;39(1):100-3.
3. Total sexual violence at the national level, number of policerecorded offences [database on the Internet]. United Nations Office on Drugs and Crime. 2012. Available from: http://www.unodc.org/documents/data-and-analysis/ statistics/crime/CTS12-Sexual-violence.xls. Accessed 25 Dec 2012.
4. Garcia FD, Thibaut F. Sexual addictions. Am J Drug Alcohol Abuse. 2010;36(5):254-60. doi:10.3109/00952990.2010.503823.
5. Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. Drugs. 2011;71(6):771-90. doi:10.2165/11585490- 000000000-00000.
6. Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010;11(4):604-55.
7. Craig LA, Browne KD, Stringer I, Hogue TE. Sexual reconviction rates in the United Kingdom and actuarial risk estimates. Child Abuse Negl. 2008;32(1):121-38. doi:10.1016/ j.chiabu.2007.09.002.
8. Hanson RK, Morton KE, Harris AJ. Sexual offender recidivism risk: what we know and what we need to know. Ann N YAcad Sci. 2003;989:154-66. discussion 236-46. (Pubitemid 36808402)
9. Hanson RK, Morton-Bourgon KE. The characteristics of persistent sexual offenders: a meta-analysis of recidivism studies. J Consult Clin Psychol. 2005;73(6):1154-63. doi:10.1037/ 0022-006X.73.6.1154. (Pubitemid 43161113)
10. Hanson RK, Morton-Bourgon KE. The accuracy of recidivism risk assessments for sexual offenders: a metaanalysis of 118 prediction studies. Psychol Assess. 2009;21:1-21.
11. Harris AJR, Hanson RK. La récidive sexuelle: d'une simplicité trompeuse. In: civile Spep, editor. Ottawa, Canada2004.
12. Prentky R, Burgess AW. Rehabilitation of child molesters: a costbenefit analysis. Am J Orthopsychiatry. 1990;60(1):108-17. (Pubitemid 20093434)
13. Schmucker M, Losel F. Does sexual offender treatment work? A systematic review of outcome evaluations. Psicothema. 2008;20(1):10-9.
14. McConaghy N. Paedophilia: a review of the evidence. Aust N Z J Psychiatr. 1998;32(2):252-65. discussion 66-7.
15. Hall RC. A profile of pedophilia: definition, characteristics of offenders, recidivism, treatment outcomes, and forensic issues. Mayo Clin Proc. 2007;82(4):457-71. (Pubitemid 46543471)
16. Rosler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med. 1998;338(7):416-22. doi:10.1056/NEJM199802123380702. (Pubitemid 28135668)
17. Murray JB. Psychological profile of pedophiles and child molesters. J Psychol. 2000;134(2):211-24.
18. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57(11):1012-30.
19. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92(2):111-8. (Pubitemid 28223582)
20. Virkkunen M, De Jong J, Bartko J, Goodwin FK, Linnoila M. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. Arch Gen Psychiatry. 1989;46(7):600-3. (Pubitemid 19180337)
21. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994;51(1):20-7. (Pubitemid 24028994)
22. Maes M, van West D, De Vos N, Westenberg H, Van Hunsel F, Hendriks D, et al. Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPPinduced cortisol responses in men with pedophilia. Neuropsychopharmacology. 2001;24(1):37-46. doi:10.1016/S0893- 133X(00)00177-9.
23. Baratta A, Javelot H, Morali A, Halleguen O, Weiner L. The role of antidepressants in treating sex offenders. Sexologies. 2012;21:106-8.
24. Hill A, Briken P, Kraus C, Strohm K, Berner W. Differential pharmacological treatment of paraphilias and sex offenders. Int J Offender Ther Comp Criminol. 2003;47(4):407-21. (Pubitemid 36935026)
25. Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C. Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.2002 Contract No.: 28.
26. Thibaut F. Pharmacological treatment of sex offenders. Sexologies. 2011;20:166-8.
27. Fedoroff JP. Antiandrogens vs serotonergic medications in the treatment of sex offenders: a preliminary compliance study. Can J Hum Sex. 1995;4:111-23.
28. Simon NG, Cologer-Clifford A, Lu SF, McKenna SE, Hu S. Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression. Neurosci Biobehav Rev. 1998;23(2):325-36. (Pubitemid 29011635)
29. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974-84. (Pubitemid 26264696)
30. Wille R, Beier KM. Castration in Germany. Ann Sex Res. 1989;2:103-33.
31. Bradford JM. The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatr. 2001;46(1):26-34. (Pubitemid 32209342)
32. Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther. 2009;31(1):1-31.
33. Krueger RB, Hembree W, Hill M. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency. Sex Abuse. 2006;18(2):227-8. doi:10.1007/s11194-006-9012- 5. (Pubitemid 44327003)
34. Jeffcoate WJ, Matthews RW, Edwards CR, Field LH, Besser GM. The effect of cyproterone acetate on serum testosterone, LH, FSH and prolactin in male sexual offenders. Clin Endocrinol. 1980;13(2):189-95. (Pubitemid 10053585)
35. Neuman F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res. 1977;9:1-13.
36. Codispoti VL. Pharmacology of sexually compulsive behavior. Psychiatr Clin N Am. 2008;31(4):671-9. doi:10.1016/ j.psc.2008.06.002.
37. Meyer JW, Cole CM. Physical and chemical castration of sex offenders. J Off Rehab. 1997;25(3-4):1-18.
38. Laschet U, Laschet L. Antiandrogens in the treatment of sexual deviations of men. J Steroid Biochem. 1975;6(6):821-6.
39. Hansen H, Lykke-Olesen L. Treatment of dangerous sexual offenders in Denmark. J Forensic Psychiatr. 1997;8:195-9. (Pubitemid 27232102)
40. Czerny JP, Briken P, Berner W. Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry. 2002;17(2):104-6. (Pubitemid 34467873)
41. Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand. 1993;87(6):445-50. (Pubitemid 23186268)
42. Thibaut F, Cordier B, Kuhn JM. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment? Psychoneuroendocrinology. 1996;21(4):411-9.
43. Thibaut F, Kuhn JM, Cordier B, Petit M. Hormone treatment of sex offenses. Encephale. 1998;24(2):132-7.
44. Schober JM, Kuhn PJ, Kovacs PG, Earle JH, Byrne PM, Fries RA. Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav. 2005;34(6):691-705. doi:10.1007/s10508-005-7929-2. (Pubitemid 41803666)
45. Brahams D. Voluntary chemical castration of a mental patient. Lancet. 1988;1(8597):1291-2.
46. Ward T, Gannon TA, Birgden A. Human rights and the treatment of sex offenders. Sex Abuse. 2007;19(3):195-216. doi:10.1007/ s11194-007-9053-4.
47. Berlin FS. Sex offender treatment and legislation. J Am Acad Psychiatry Law. 2003;31(4):510-3. (Pubitemid 38120795)
48. Silverman WA. The myth of informed consent: in daily practice and in clinical trials. J Med Ethics. 1989;15(1):6-11. (Pubitemid 20099131)
49. Belgian Advisory Commitee on Bioethics. Opinion no. 39 of December 18th 2006 on hormonal treatment of sex offender. 2006. In: http://www.health.belgium. be/internet2Prd/groups/public/@public/@dg1/@legalmanagement/documents/ie2divers/ 18074794.pdf. Accessed 16 Feb 2011.
50. Moulier V, Fonteille V, Pelegrini-Issac M, Cordier B, Baron- Laforet S, Boriasse E, et al. A pilot study of the effects of gonadotropin-releasing hormone agonist therapy on brain activation pattern in a man with pedophilia. Int J Offender Ther Comp Criminol. 2012;56(1):50-60. doi:10.1177/ 0306624X10392191.